Search review questions

Mortality (timing of outcome measurement unclear) · critically ill adults

Infectious complications (independent of specific site, as defined by the trial authors) ( · critically ill adults

Feed intolerance or gastrointestinal complications (as defined by the authors) · critically ill adults

Survival at hospital discharge · adults and children more than 4 weeks old suffering from OHCA

Survival at 30 days · adults and children more than 4 weeks old suffering from OHCA

Neurological function at hospital discharge, measured by cerebral performance category (CPC) · adults and children more than 4 weeks old suffering from OHCA

Neurological function at 30 days, measured by cerebral performance category (CPC) · adults and children more than 4 weeks old suffering from OHCA

Cardiopulmonary resuscitation performed before EMS arrival · adults and children more than 4 weeks old suffering from OHCA

Defibrillation performed before EMS arrival · adults and children more than 4 weeks old suffering from OHCA

Survival to hospital admission · adults and children more than 4 weeks old suffering from OHCA

Comparison: outcome · participants at risk of high altitude illness

Iron supplementation versus placebo: risk of AMS · participants at risk of high altitude illness

Rhodiola crenulata versus placebo: risk of AMS · participants at risk of high altitude illness

Comparison: outcome · participants at risk of high altitude illness

Ginkgo biloba versus acetazolamide: risk of AMS · participants at risk of high altitude illness

Acetazolamide + ginkgo biloba versus ginkgo biloba: risk of AMS · participants at risk of high altitude illness

Acetazolamide + ginkgo biloba versus acetazolamide: risk of AMS · participants at risk of high altitude illness

Acetazolamide versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness

Acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness

Acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS · participants at risk of high altitude illness

Normal versus simulated altitude conditions: risk of AMS · participants at risk of high altitude illness

Positive end‐expiratory pressure (PEEP) versus nothing: risk of AMS · participants at risk of high altitude illness

Remote ischaemic preconditioning (RIPC) versus placebo: risk of AMS · participants at risk of high altitude illness

Comparisons: outcome · participants at risk of high altitude illness

Antioxidants versus placebo: risk of AMS · participants at risk of high altitude illness

Ginkgo biloba versus placebo: risk of AMS · participants at risk of high altitude illness

Erythropoietin versus placebo: risk of AMS · participants at risk of high altitude illness

Medroxyprogesterone versus placebo: risk of AMS · participants at risk of high altitude illness

Mortality in hospital: death occurring during the hospital stay · critically‐ill adults

Mortality in ICU: death occurred during the ICU stay · critically‐ill adults

Mortality at 30 days: 28 to 30 days all‐cause mortality · critically‐ill adults

Length of hospital stay: days stayed in the hospital · critically‐ill adults

Length of ICU stay: days stayed in the ICU · critically‐ill adults

Infectious complications: events of any type of infectious complications occurred during the hospital stay, registered by the study authors according to their diagnostic criteria of infections. · critically‐ill adults

Length of mechanical ventilation: days on mechanical ventilation during ICU stay · critically‐ill adults

Outcomes and intervention · people suffering from high altitude illness

All‐cause mortality · people suffering from high altitude illness

Complete relief of AMS symptoms · people suffering from high altitude illness

Reduction in symptom score severity at 12 hours (Clinical score: ranged from 0 to 11 (worse)) Intervention: Simulated descent of 193 millibars versus 20 millibars · people suffering from high altitude illness

Adverse effects during treatment Intervention: Hyperbaric chamber/ 160 millibars versus supplementary oxygen · people suffering from high altitude illness

All‐cause mortality · people suffering from high altitude illness

Complete relief of AMS symptoms (12 to 16 hours after treatment) Scale used: Acute Mountain Sickness score (ranged from 0 to 9 (worse)) · people suffering from high altitude illness

Reduction in symptom score severity Time of measurement: 1 to 48 hours after treatment, end of treatment Scale of measurement: Self‐administered AMS questionnaires (ranged from 0 to 90 (worse)), AMS Symptom Questionnaire (ranged from 0 to 22 (wors... · people suffering from high altitude illness

Adverse effects Time of measurement: 1 to 48 hours after treatment, end of treatment Scale of measurement:not stated · people suffering from high altitude illness

Duration of mechanical ventilation (measured in hours for the entire duration of the first ICU stay for each patient) · mechanically ventilated ICU adults and children requiring sedation management

ICU mortality · mechanically ventilated ICU adults and children requiring sedation management

Hospital mortality · mechanically ventilated ICU adults and children requiring sedation management

ICU length of stay (days) · mechanically ventilated ICU adults and children requiring sedation management

Hospital length of stay (days) · mechanically ventilated ICU adults and children requiring sedation management

Adverse event ‐ incidence of self‐extubation (in ICU) · mechanically ventilated ICU adults and children requiring sedation management